Which medicines and herbal products are damaging livers? egyptian hospital launches Two-Year hunt
NCT ID NCT07830901
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers at Al-Rajhi Liver Hospital in Assiut, Egypt, are studying drug-induced liver injury, a form of liver damage caused by prescription medicines, over-the-counter drugs, herbal products, or dietary supplements. The study has two parts: a review of past medical records from adults already diagnosed with the condition, and a follow-up of adults who develop it during a later period. The team aims to measure how common the injury is, identify the products most often involved, classify the pattern of liver damage, and find which patients are more likely to face serious outcomes such as liver failure, transplant, or death. Participants receive standard medical care from their own doctors; researchers only record routine test results and treatment details.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the study maps which medicines, herbs, and supplements harm the liver most often in this region, doctors could spot drug-induced liver injury earlier and warn patients away from the riskiest products.
- What could go wrong
- This is an observational study at a single hospital, so its numbers may not reflect other regions or hospitals. It cannot prove that any specific product causes liver damage, only describe patterns among patients who already have it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (aged 18 years or older) presenting to or admitted to Al-Rajhi Liver Hospital, Assiut University Hospitals, Assiut, Egypt, who fulfill the predefined clinical and biochemical criteria for drug-induced liver injury (DILI) following exposure to a suspected prescription drug, herbal preparation, or dietary supplement.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients aged 18 years or older. * Patients presenting to or admitted to Al-Rajhi Liver Hospital during the study period. * Patients fulfilling the predefined biochemical and clinical criteria for drug-induced liver injury (DILI): * Alanine aminotransferase (ALT) \>= 5 times the upper limit of normal (ULN); or * Alkaline phosphatase (ALP) \>= 2 times the ULN (particularly when accompanied by elevated gamma-glutamyl transferase \[GGT\] and in the absence of a known bone source); or * ALT \>= 3 times the ULN with simultaneous total bilirubin \> 2 times the ULN. * Documented exposure to a suspected medication, herbal preparation, or dietary supplement preceding the onset of liver injury, with a compatible temporal relationship. * For the retrospective cohort: availability of adequate medical records to establish the diagnosis of DILI and assess clinical outcomes. * For the prospective cohort: provision of informed consent for study participation and follow-up (by the patient or a legally authorized representative). Exclusion Criteria: * Patients younger than 18 years * Patients in whom an alternative etiology of acute liver injury is clearly established (e.g., acute viral hepatitis, autoimmune hepatitis, biliary obstruction, ischemic/hypoxic hepatitis) and DILI is considered unlikely * Patients with insufficient clinical or laboratory data to verify whether diagnostic criteria for DILI are fulfilled * Patients in the retrospective cohort with inadequate outcome records where assessment of the primary clinical endpoint is not possible * Patients (or their legal representatives) who decline participation in the prospective cohort
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug-induced liver injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may solve tricky liver diagnosis puzzle
- New study aims to uncover the impact of itching in liver injury patients
- Massive study tracks hidden liver dangers of common drugs and herbal remedies
- New study collects data and samples to unlock mysteries of Drug-Induced liver damage
- Blood cancer patients may get liver protection from common drug
- Milk thistle extract may help repair Medication-Damaged livers